Search

everythinglearnresearchcommunity

for

Search:↓

A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

The user has been using a combination of treatments including Dutasteride, Minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy to address hair loss but continues to experience shedding and density loss. Despite high testosterone and iron levels, the user is frustrated with the lack of improvement and is considering adjusting treatment or exploring other options like a hair transplant.

A user is concerned about a change in the formula of Sons topical treatment, which now requires fewer sprays but contains less minoxidil. They question if the change is for convenience or if it's a way to charge the same for less product.

A 28-year-old male is experiencing temple regrowth but crown thinning while using 5mg minoxidil and 0.5mg dutasteride. The shedding phase is seen as a positive sign of treatment effectiveness, with expectations of noticeable improvements around 6 to 12 months.

A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.

The conversation discusses androgenetic alopecia (AGA) and questions why treatments focus on lowering DHT levels instead of building resistance to it. It also touches on hair transplantation techniques using body hair.

The user tried a product labeled as PP405 from Umbrella Labs for hair loss but saw no changes, and it was revealed to be a fake or misidentified product. The user is also using finasteride, minoxidil, and other treatments but is still experiencing hairline issues.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.

Alternating between finasteride and dutasteride is being considered due to cost concerns. The user is worried about losing progress if switching entirely to dutasteride.

The user switched from finasteride to dutasteride and experienced noticeable hair regrowth without side effects, though some users questioned the necessity of such a potent treatment given the minimal hair loss. The conversation also touched on potential side effects of dutasteride, such as reduced sperm quality, but the user reported no issues.

The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.

The conversation discusses identifying permanent hair loss and includes treatments like microneedling and biotin vitamins. The user is unsure whether the reduction in wispy hairs is due to hair revitalization or loss.

The user is experiencing significant hair shedding after starting RU58841, despite using dutasteride and oral minoxidil for over a year without stabilization. Others suggest continuing the treatment as shedding can be a normal phase, but caution that RU58841 is unpredictable.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

The conversation discusses using Sandalore for hair loss treatment, with a focus on finding the correct concentration for a topical lotion. The consensus is to start with a 0.1% concentration due to potential scalp irritation at higher levels.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

The user has been taking 1.25mg of oral minoxidil and 1mg of finasteride for a year and added topical minoxidil in January. They noticed hair improvement but are experiencing uneven regrowth, with the hairline improving and the middle part worsening.

The conversation is about a user experiencing hair loss who has been using finasteride for a year and minoxidil once a day for five months, but still experiences shedding and thin hair. The user is considering switching to dutasteride next year and shares their progress with others using similar treatments.

The post discusses the experiences of individuals with diffuse hair thinning using finasteride, with many reporting no improvement or worsening conditions after 6 months. Various suggestions include persisting with the treatment, checking for underlying conditions, adding minoxidil for volume, adjusting dosage, and considering other potential causes like autoimmune responses and inflammation.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.

A 43-year-old male has been using oral minoxidil, finasteride, and dutasteride for hair loss, with some stabilization and thin hair growth but no significant cosmetic improvement. He is considering increasing microneedling frequency and exploring other options, as he is concerned about the lack of terminal hair growth.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.

The conversation discusses using RU58841 mixed with topical minoxidil for hair loss, noting its chemical instability and storage challenges. A user shares their experience using RU58841 with ethanol and propylene glycol, mentioning no significant results yet.

A 20-year-old with diffused thinning is using oral minoxidil for androgenetic alopecia. They plan to switch to topical minoxidil, finasteride, and bimatoprost, and may consider surgery if their condition improves.